Clinical implications of chromosomal aberrations (13q14 and
17p13 deletion, translocation t(4;14) and 1q21 amplification)
in patients with relapsed multiple myeloma treated by
thalidomide or bortezomib (Velcade)

D 2007

Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)

ZAORALOVÁ, Romana, Petr KUGLÍK, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC et. al.

Basic information

Original name

Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)

Name in Czech

Klinické důsledky výskytu chromozomálních aberací (delece 13q14 a 17p13, translokace t(4;14) a amplifikaci 1q21) u pacientů s mnohočetným myelomem léčených thalidomodem nebo bortezomibem (Velcade)

Authors

ZAORALOVÁ, Romana (203 Czech Republic), Petr KUGLÍK (203 Czech Republic, guarantor), Hana FILKOVÁ (203 Czech Republic), Henrieta GREŠLIKOVÁ (703 Slovakia), Pavel NĚMEC (203 Czech Republic), Alexandra OLTOVÁ (203 Czech Republic), Luděk POUR (203 Czech Republic), Zdeněk ADAM (203 Czech Republic), Andrea KŘIVANOVÁ (203 Czech Republic), Marta KREJČÍ (203 Czech Republic) and Roman HÁJEK (203 Czech Republic)

Edition

Brno, From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual, p. 12-13, 2 pp. 2007

Publisher

vydavatelství Masarykovy Univerzity

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

Genetics and molecular biology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14310/07:00019107

Organization unit

Faculty of Science

ISBN

978-80-210-4417-3

Keywords in English

Multiple myeloma; CKS1B amplification; RB deletion; p53 deletion; t(4;14); cIg FISH

Abstract

ORIG CZ

V originále

The aim of the work was: 1) To study the incidence of the chromosomal aberrations known as adverse prognostic factors in MM - deletion of 13q14 (RB1), deletion of 17p13 (p53), amplification of 1q21 (CKS1B) and translocation t(4;14) in a group of 40 patients with relapsed MM. 2) To compare the prognostic and predictive significance of these unfavorable chromosomal aberrations in patients with relapsed MM treated with thalidomide or bortezomib (Velcade) based regimens.

In Czech

V práci je shrnutí našich současných poznatků o vlivu cytogenetických negativních prognostických markerů u nemocných mnohočetným myelomem léčených novými léky.

Links

LC06027, research and development project

Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

MSM0021622415, plan (intention)

Name: Molekulární podstata buněčných a tkáňových regulací

Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations

NR9317, research and development project

Name: Prognostický význam klonálních chromosomových aberací při použití nových léčebných metod u mnohočetného myelomu

Citovat

ZAORALOVÁ, Romana, Petr KUGLÍK, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade). In From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual. Brno: vydavatelství Masarykovy Univerzity, 2007, p. 12-13. ISBN 978-80-210-4417-3.

@inproceedings{726821,
   author = {Zaoralová, Romana and Kuglík, Petr and Filková, Hana and Grešliková, Henrieta and Němec, Pavel and Oltová, Alexandra and Pour, Luděk and Adam, Zdeněk and Křivanová, Andrea and Krejčí, Marta and Hájek, Roman},
   address = {Brno},
   booktitle = {From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual},
   keywords = {Multiple myeloma; CKS1B amplification; RB deletion; p53 deletion; t(4;14); cIg FISH},
   language = {eng},
   location = {Brno},
   isbn = {978-80-210-4417-3},
   pages = {12-13},
   publisher = {vydavatelství Masarykovy Univerzity},
   title = {Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)},
   year = {2007}
}

TY  - JOUR
ID  - 726821
AU  - Zaoralová, Romana - Kuglík, Petr - Filková, Hana - Grešliková, Henrieta - Němec, Pavel - Oltová, Alexandra - Pour, Luděk - Adam, Zdeněk - Křivanová, Andrea - Krejčí, Marta - Hájek, Roman
PY  - 2007
TI  - Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)
PB  - vydavatelství Masarykovy Univerzity
CY  - Brno
SN  - 9788021044173
KW  - Multiple myeloma
KW  - CKS1B amplification
KW  - RB deletion
KW  - p53 deletion
KW  - t(4;14)
KW  - cIg FISH
N2  - The aim of the work was: 1) To study the incidence of the chromosomal aberrations known as adverse prognostic factors in MM - deletion of 13q14 (RB1), deletion of 17p13 (p53), amplification of 1q21 (CKS1B) and translocation t(4;14) in a group of 40 patients with relapsed MM. 2) To compare the prognostic and predictive significance of these unfavorable chromosomal aberrations in patients with relapsed MM treated with thalidomide or bortezomib (Velcade) based regimens.
ER  -

ZAORALOVÁ, Romana, Petr KUGLÍK, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade). In \textit{From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual}. Brno: vydavatelství Masarykovy Univerzity, 2007, p.~12-13. ISBN~978-80-210-4417-3.

Detailed Information on Publication Record